The treatment was approved in 2024 for chronic graft-vs-host disease after failure of at least 2 prior lines of systemic therapy in patients weighing at least 40kg. The Food and Drug ...
Hosted on MSN2mon
Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vialsIncyte (NASDAQ:INCY) and Syndax Pharmaceuticals (SNDX) have received FDA approval for their drug Niktimvo in 9 mg and 22 mg vial sizes. Niktimvo was approved in August 2024 for the treatment of ...
Following FDA approval of the new vial sizes, the companies anticipate launching Niktimvo in the U.S. no later than the early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback